This classifier was created using the semi‐quantitative tau lesion burdens (i.e., NFT, astrocytic inclusions [tufted astrocytes in PSP and astrocytic plaques in CBD], coiled bodies and tau threads) in vulnerable brain regions in PSP and CBD (i.e., caudate nucleus, red nucleus and motor cortex).19 The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.